Completed INTERVENTIONAL 2-arm NCT05133739

RHA®4 for Midface Volume Deficiency

A Randomized, Blinded Evaluator, Multicenter, Prospective, Between-subjects Clinical Study to Evaluate Safety and Effectiveness of RHA®4 for the Treatment of Midface Volume Deficiency

Sponsor: Teoxane SA

Conditions Cheek Augmentation Correction of Age-related Midface Contour Deficiencies

Interventions injection of Comparator Product in Midface injection of RHA®4 in Midface

Updated 5 times since 2021 Last updated: Feb 27, 2025 Started: Oct 29, 2021 Primary completion: Jan 17, 2023 Completion: Jan 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Cheek Augmentation and Correction of Age-related Midface Contour Deficiencies, this trial is completed. The trial is conducted by Teoxane SA and has accumulated 5 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Apr 2025 — Present [monthly]

Completed

Status: Withheld → Completed
Sep 2024 — Apr 2025 [monthly]

Withheld
Aug 2023 — Sep 2024 [monthly]

Withheld
Jul 2022 — Aug 2023 [monthly]

Withheld
Dec 2021 — Jul 2022 [monthly]

Withheld

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teoxane SA

Data source: Teoxane SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chestnut Hill, United States